FDA Clears TMS for OCD; Cerebral Pauses ADHD Scripts; Binge-Eating Drug Flops

The FDA cleared the transcranial magnetic stimulation system NeuroStar Advanced Therapy for the treatment of obsessive-compulsive disorder, Neuronetics announced. The system was previously cleared for major depressive disorder.

Depression and anxiety were linked with a higher rate of accumulating newly diagnosed chronic conditions in young men and women. (JAMA Network Open)

The online mental health provider Cerebral said it will no longer write scripts for attention-deficit/hyperactivity disorder medications, including Adderall and Ritalin, now that the Drug Enforcement Agency launched an investigation into reports of overprescribing. (Fierce Healthcare)

Are the FDA’s risk evaluation and mitigation strategy (REMS) program requirements blocking patients with treatment-resistant schizophrenia from access to treatment? (STAT)

Females ages 8 to 19 who attempted suicide had a 6-fold higher risk for subsequent hospitalization for substance use disorders, a study from Canada found, plus a 67-fold higher risk for developing sedative or hypnotic use disorders in the 5 years after an attempt. (JAMA Psychiatry)

After failing to meet the primary endpoint, Idorsia Pharmaceuticals said it’s throwing in the towel on the investigational binge-eating disorder drug ACT-539313, a selective orexin 1 receptor antagonist. (BioSpace)

Alzamend Neuro announced it started a phase IIa trial of its investigational treatment AL001 — a novel lithium-delivery system — for Alzheimer’s-related dementia, with topline data expected in December.

Researchers at Indiana University are developing a wearable opioid overdose detection patch that would automatically administer naloxone if signs of an impending overdose are detected.